Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 30, Issue 20, 2012, Pages 2483-2491

  Claus, Rainer ^a   Lucas, David M ^c   Stilgenbauer, Stephan ^b   Ruppert, Amy S ^c   Yu, Lianbo ^d   Zucknick, Manuela ^a   Mertens, Daniel ^a,b   Buḧler, Andreas ^b   Oakes, Christopher C ^a   Larson, Richard A ^f   Kay, Neil E ^g   Jelinek, Diane F ^g   Kipps, Thomas J ^h   Rassenti, Laura Z ^h   Gribben, John G ⁱ   Doḧner, Hartmut ^b   Heerema, Nyla A ^e   Marcucci, Guido ^c   Plass, Christoph ^a   Byrd, John C ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c OHIO STATE UNIVERSITY   (United States)

^d Center for Biostatistics   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CPG DINUCLEOTIDE; CYCLOPHOSPHAMIDE; DINUCLEOTIDE; FLUDARABINE; PENTOSTATIN; PROTEIN KINASE ZAP 70; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEASIBILITY STUDY; FEMALE; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; ZAP 70 GENE;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; REGULATORY SEQUENCES, NUCLEIC ACID; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84864071185     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.3090     Document Type: Article

References (23)

1. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999 (Pubitemid 29430400)
2. Fais F, Ghiotto F, Hashimoto S, et al: Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102:1515-1525, 1998 (Pubitemid 28492218)
3. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999 (Pubitemid 29430399)
4. Rassenti LZ, Jain S, Keating MJ, et al: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112:1923-1930, 2008
5. Zenz T, Mertens D, Küppers R, et al: From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50, 2010
6. Rosenwald A, Alizadeh AA, Widhopf G, et al: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639-1647, 2001 (Pubitemid 33126814)
7. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003 (Pubitemid 36514707)
8. Sivina M, Hartmann E, Kipps TJ, et al: CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 117:1662-1669, 2011
9. Messmer D, Fecteau JF, O'Hayre M, et al: Chronic lymphocytic leukemia cells receive RAFdependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 117:882-889, 2011
10. Chen L, Widhopf G, Huynh L, et al: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609-4614, 2002 (Pubitemid 35429705)
11. Chen L, Apgar J, Huynh L, et al: ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105:2036-2041, 2005 (Pubitemid 40731789)
12. Del Poeta G, Del Principe MI, Consalvo MA, et al: The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 104:2743-2752, 2005 (Pubitemid 41798284)
13. Brown JR, Levine RL, Thompson C, et al: Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia 22:1966-1969, 2008
14. Corcoran M, Parker A, Orchard J, et al: ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 90:1078-1088, 2005 (Pubitemid 41323507)
15. Chantepie SP, Vaur D, Grunau C, et al: ZAP-70 intron1 DNA methylation status: Determination by pyrosequencing in B chronic lymphocytic leukemia. Leuk Res 34:800-808, 2010
16. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapywithpentostatin,cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007 (Pubitemid 46105933)
17. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003 (Pubitemid 36025880)
18. Woyach JA, Ruppert AS, Heerema NA, et al: Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712. J Clin Oncol 29:1349-1355, 2011
19. Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004 (Pubitemid 39096916)
20. Byrd JC, Gribben JG, Peterson BL, et al: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24:437-443, 2006 (Pubitemid 46655595)
21. Kienle D, Benner A, Kröber A, et al: Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 107:2090-2093, 2006 (Pubitemid 43289393)
22. Ehrich M, Nelson MR, Stanssens P, et al: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 102:15785-15790, 2005 (Pubitemid 41552820)
23. Tost J, Dunker J, Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 35:152-156, 2003 (Pubitemid 36828725)